Entries by gigamune

GigaMune wins its seventh SBIR grant

GigaMune won its seventh SBIR grant, entitled “Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy” from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The project seeks to expand the capabilities of GigaMune’s technology into delivery of curative transgenes to muscle cells. GigaMune’s Founder and CEO Dr. David […]

Podium presentation by Dr. David Johnson at the 2023 CAR/TCR Summit

Dr. David Johnson, Founder and CEO of GigaMune, presented the GigaMune team’s latest research on methods and compositions for discovering novel pseudotypes for virus like particle gene delivery at the 2023 CAR/TCR Summit held in Boston, Massachusetts. Dr. Johnson described his team’s groundbreaking methods for searching quadrillions of nucleotides of sequence data for discovery of […]

GigaMune closes pre-seed financing round

GigaMune, a new biotech based in San Francisco, recently closed a pre-seed financing round to support its initial efforts to develop novel in vivo cell therapeutics for cancer and inherited disease. GigaMune’s technology relies on methods to search quadrillions of nucleotides for proteins such as viral receptors, new technologies for artificial intelligence to optimize protein […]